Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation
Mariam T. Nawas(University of Chicago), Rebecca L. Olin(University of California, San Francisco), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Lloyd E. Damon(University of California, San Francisco), Ying Sheng(University of California, San Francisco), Charalambos Andreadis(University of California, San Francisco), Aaron C. Logan(University of California, San Francisco), Chiung‐Yu Huang, Thomas Martin(University of California, San Francisco), Jeffrey L. Wolf(City College of San Francisco), Gabriel N. Mannis(Stanford University), Weiyun Z. Ai(City College of San Francisco)
Cited by 7
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782